Source: Annual Congress 2009 - Tuberculosis control
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Tabarsi, V. Tabatabaei, E. Chitsaz, P. Baghaei, M. Marjani, M. Shamaei, M. Amiri, D. Mansouri, M. Masjedi, M. van der Werf (Tehran, Islamic Republic Of Iran; The Hague, Netherlands). Revised CAT II regimen as an alternative strategy for re-treatment of CAT I regimen failure and irregular treatment cases. Eur Respir J 2009; 34: Suppl. 53, 2609

Member's Comments

No comment yet.

Related content which might interest you: Outcome in DOTS category II patients by strengthening the regimen with daily levofloxacin Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Short 12-month regimen with intravenouse linezolid for MDR-TB:  treatment outcomes and first follow up results. Source: International Congress 2018 – New developments in tuberculosis Year: 2018 Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 Resistance pattern to WHO CAT IV regimen in patients suspected of drug resistance tuberculosis presenting to a specialist office practice in Mumbai Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS) Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Weekly chemotherapy with cisplatin/paclitaxel in the front-line treatment of NSCLC: a phase II study Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Glucocorticosteroid treatment in sarcoidosis: comparison of regimens Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Three drug regimen in SCLC-ED patients: a phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007